Make an Inquiry
Accelerating Phenylketonuria Drug Development

Phenylketonuria (PKU) presents significant therapeutic challenges due to its complex metabolic underpinnings and lifelong impact on patients. Ace Therapeutics is dedicated exclusively to advancing drug development for PKU, serving as a specialized partner for organizations seeking innovative, effective therapeutic solutions. Ace Therapeutics offers comprehensive preclinical services spanning target validation, lead optimization, pharmacology, and IND-enabling studies, ensuring a seamless transition from discovery to clinical development. Our scientific team brings deep expertise in metabolic disorders and leverages state-of-the-art platforms for in vitro and in vivo evaluation, biomarker analysis, and mechanistic studies tailored to the unique biology of PKU. All research is conducted in strict accordance with current regulatory guidelines, supporting robust, submission-ready data packages. By integrating advanced scientific capabilities with rigorous quality standards, Ace Therapeutics accelerates the development of novel PKU therapies. Our unwavering commitment is to empower partners with the expertise and resources needed to deliver transformative treatments for PKU patients worldwide.

What is PhenylketonuriaTargets for PhenylketonuriaDrug Discovery and Development ServicesWhy Choose Us

What is Phenylketonuria

Phenylketonuria (PKU) is a rare inherited metabolic disorder caused by mutations in the PAH gene, which encodes the hepatic enzyme phenylalanine hydroxylase. This enzyme is essential for converting the amino acid phenylalanine into tyrosine. Deficiency or absence of PAH activity leads to the accumulation of phenylalanine in the blood and brain, resulting in neurotoxic effects. PKU is primarily inherited in an autosomal recessive manner and varies in severity, ranging from classic PKU with near-complete enzyme deficiency to milder forms with partial activity. In some cases, defects in the synthesis or recycling of tetrahydrobiopterin (BH4), a cofactor for PAH, can also cause elevated phenylalanine levels and additional neurological symptoms. Clinically, untreated PKU can cause intellectual disability, developmental delays, microcephaly, seizures, behavioral problems, and psychiatric disorders. Other features may include hypopigmentation, eczema, and a musty odor of the skin or urine. Diagnosis is established through newborn screening, which measures blood phenylalanine levels, followed by confirmatory biochemical and genetic tests. Early detection is crucial to prevent irreversible neurological damage. Treatment primarily involves a lifelong, phenylalanine-restricted diet. Pharmacological options include sapropterin dihydrochloride, which enhances residual PAH activity in responsive patients, and pegvaliase, an enzyme substitution therapy that degrades excess phenylalanine. BH4 deficiency requires specific management with cofactor and neurotransmitter supplementation.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
pegvaliase (Rec INN); pegvaliase-pqpz 1585984-95-7
img-69056-38-8-dapropterin-dihydrochloridesapropterin-dihydrochlo dapropterin dihydrochloride; sapropterin dihydrochloride (Rec INNM; USAN) 69056-38-8 C9 H15 N5 O3 . 2 Cl H 314.169

Learn More

Targets for Phenylketonuria

The central therapeutic targets in Phenylketonuria (PKU) are enzymes directly responsible for phenylalanine metabolism, most notably phenylalanine hydroxylase (PAH) in humans and its murine ortholog, Pah, in mice. PAH is a hepatic enzyme that catalyzes the conversion of phenylalanine to tyrosine, a critical step for preventing toxic buildup of phenylalanine. Structurally, PAH functions as a homotetramer and requires tetrahydrobiopterin (BH4) as a cofactor, with its activity regulated by substrate binding, phosphorylation, and cofactor availability. Mutations in PAH disrupt this process, leading to phenylalanine accumulation and neurotoxicity, the hallmark of PKU. The pathogenic role of PAH deficiency is strongly supported by genetic, biochemical, and clinical evidence, and is faithfully recapitulated in mouse models with Pah mutations, which are essential for preclinical research. Therapeutically, targeting PAH has led to the development of several interventions, including enzyme substitution (pegvaliase), gene therapy, and BH4 supplementation (sapropterin dihydrochloride) for responsive genotypes. These strategies aim to restore or compensate for deficient PAH activity, thereby reducing phenylalanine levels and preventing neurological damage. Mouse models with Pah mutations have been instrumental in advancing these therapies from bench to bedside, validating their efficacy and safety. The direct, mechanistic involvement of PAH in PKU pathogenesis makes it a robust and actionable target, supporting ongoing precision medicine approaches and the development of novel treatments to improve patient outcomes.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our in vitro efficacy testing service accelerates Phenylketonuria drug discovery by providing robust, customizable assays targeting key enzymes and transporters such as phenylalanine hydroxylase, SLC6A19, and TMPRSS15. Utilizing advanced techniques including mass spectrometry, fluorescence, calorimetry, and uptake assays, we quantify compound potency, efficacy, and binding affinity. Critical pharmacological parameters like EC-50, IC-50, and Kd are precisely measured to support lead optimization. Our comprehensive platforms deliver reliable, actionable data on biochemical and cellular mechanisms, enabling informed decision-making and effective preclinical evaluation of candidate therapies for improved management of Phenylketonuria.

Phenylalanine Hydroxylase Solute Carrier Family 6 Member 19
Transmembrane Serine Protease 15

Learn More

Why Choose Us

Choosing Ace Therapeutics means partnering with a team that possesses deep, specialized expertise in Phenylketonuria research and drug development. Our dedicated scientists and professionals have years of experience addressing the unique challenges of Phenylketonuria, leveraging advanced technology platforms that enable precise and innovative solutions throughout the drug discovery and development process. Ace Therapeutics has established a strong track record for delivering reliable, high-quality preclinical drug development services, consistently meeting project milestones and exceeding client expectations. We adhere to the highest quality standards and maintain full regulatory compliance, ensuring that every stage of our work upholds rigorous scientific and ethical guidelines. Our commitment to advancing Phenylketonuria therapeutics is unwavering; we strive to accelerate the development of safe, effective treatments that can make a meaningful difference in patients’ lives. By choosing Ace Therapeutics, you gain a trusted partner dedicated to excellence, innovation, and tangible progress in the fight against Phenylketonuria.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing new drugs for Phenylketonuria (PKU)?

A: One of the primary preclinical research challenges for PKU drug development is the establishment of robust and predictive animal models that accurately recapitulate the human disease phenotype, especially in terms of phenylalanine metabolism and neurological outcomes. Additionally, the rarity of the disease limits the availability of patient-derived biological samples for in vitro studies. Ensuring that candidate compounds effectively lower phenylalanine levels without off-target effects or toxicity is also a critical challenge.

Q: What are the key regulatory considerations during preclinical development of drugs targeting Phenylketonuria?

A: For PKU, regulatory agencies such as the FDA and EMA require comprehensive data demonstrating both the efficacy and safety of new therapies in relevant preclinical models before IND/IMPD submission. Given the pediatric nature of PKU, special attention must be paid to juvenile toxicity studies and long-term safety. Orphan drug designation is often sought, which can provide incentives but also requires robust documentation of disease rarity and unmet need.

Q: What technical aspects are important to consider in preclinical research for Phenylketonuria?

A: Key technical considerations include the development and validation of sensitive assays to quantify phenylalanine and its metabolites in biological matrices, as well as the use of gene editing or transgenic animal models that closely mimic the human PKU genotype. Additionally, formulation development for oral or enzyme replacement therapies must address stability and bioavailability challenges, particularly for pediatric administration.

Q: What are the typical timeline and cost considerations for preclinical development of PKU drugs?

A: Preclinical development for PKU drugs generally spans 18-36 months, depending on the complexity of the therapeutic modality and the need for specialized animal models. Costs can range from $2 million to $8 million, covering in vitro screening, in vivo efficacy and safety studies, pharmacokinetics, and regulatory toxicology. Early engagement with regulatory authorities and efficient study design can help optimize both timelines and costs.

Q: What are the critical success factors in preclinical drug development for Phenylketonuria?

A: Success in PKU preclinical drug development hinges on the integration of disease-relevant models, precise biomarker measurement, and early identification of potential safety concerns. Collaboration with academic experts, patient advocacy groups, and regulatory consultants can enhance the translational relevance of preclinical findings. Furthermore, a clear regulatory strategy and robust data package are essential for smooth progression to clinical development.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © Ace Therapeutics. All rights reserved.